Prometheus acquires Lotronex from GSK

Published: 9-Nov-2007

Prometheus Laboratories, a speciality pharmaceutical company based in North Carolina, has acquired exclusive rights to Lotronex (alosetron hydrochloride) tablets in the US from GlaxoSmithKline.


Prometheus Laboratories, a speciality pharmaceutical company based in North Carolina, has acquired exclusive rights to Lotronex (alosetron hydrochloride) tablets in the US from GlaxoSmithKline.

Lotronex is the only prescription drug approved by the FDA for use in adult female patients with severe diarrhea-predominant irritable bowel syndrome who meet the conditions stated in the label.

Prometheus will market and sell Lotronex under an exclusive distribution agreement until the acquisition is completed, which is expected in January 2008.

Prometheus will continue to offer Lotronex exclusively through the currently established Prescribing Program for LotronexTM (PPL). Lotronex may be prescribed only by physicians who have enrolled in the PPL.

You may also like